【摘要】 目的:观察门冬氨酸钾镁联合普罗帕酮治疗心律失常的疗效和安全性。方法:156例心律失常患者,按照临床病种和心律失常类型随意平均分为两组:治疗组78例,采用门冬氨酸钾镁片联合普罗帕酮治疗,门冬氨酸酸钾镁片2片,tid,普罗帕酮0.3～0.6g·d^-1。对照组78例,单独使用普罗帕酮治疗。两组疗程均为1个月。结果:治疗组总有效率为89.7%,明显高于对照组（66.7%,P<0.01）。不良反应发生率治疗组明显低于对照组。结论:门冬氨酸钾镁联合普罗帕酮显著提高心律失常临床疗效,明显减少单独用药时不良反应的发生。更多还原

【Abstract】 Objective: To evaluate the effects of combination of propafenone with potassium magnesium aspartate versus propafenone alone in the treatment of arrhythmia. Methods: 156 patients with arrhythmia were equally randomized to receive either propafenone (0. 3～0. 6g,qd) plus potassium magnesium aspartate (2 tablets, tid) or propafenone alone (0. 3～0. 6g, qd) for one month. Results: The overall effective rate of the bi-therapy group was 89. 7% compared with 66. 7% in the monotherapy group (P<0.01). The incidence of adverse events was lower in the bi-therapy group. Conclusion: The adjunctive therapy provided more superiority to monotherapy in patients with arrhythmia.更多还原